Cas:46181-30-0 2-METHYL-6-PHENYLPYRIDINE manufacturer & supplier

Chemical Name:2-METHYL-6-PHENYLPYRIDINE

CAS.NO:46181-30-0

Synonyms:2-methyl-6-phenylpyridine

Molecular Formula:C₁₂H₁₁N

Molecular Weight:169.22200

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:268.5ºC at 760 mmHg

Density:1.03 g/cm3

Index of Refraction:1.568

PSA:12.89000

Exact Mass:169.08900

LogP:3.05700

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-methyl-6-phenylpyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-6-phenylpyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methyl-6-phenylpyridine Use and application,2-methyl-6-phenylpyridine technical grade,usp/ep/jp grade.

Related News: It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation. 2-METHYL-6-PHENYLPYRIDINE manufacturer Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2-METHYL-6-PHENYLPYRIDINE supplier In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. 2-METHYL-6-PHENYLPYRIDINE vendor It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation. 2-METHYL-6-PHENYLPYRIDINE factory Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data.